PRGO Perrigo Company PLC

Perrigo restated over $1 billion in financial misstatements from 2015-2017. Shares plunged more than 62% after accounting and earnings disclosures. The next 100%+ earnings move could hit this month. See how to find it live on Wednesday →

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Review Perrigo's (PRGO) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

The heavy selling pressure might have exhausted for Perrigo (PRGO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Perrigo ( NYSE:PRGO ) , a major supplier of over-the-counter ( OTC ) self-care products across North America and Europe, released its Q2 FY2025 financial results on August 6, 2025. The company posted adjusted earnings per share of $0.57, missing the consensus non-GAAP EPS estimate of $0.59.

PRGO tops Q2 EPS but misses revenue. trims 2025 sales outlook, sending shares down in pre-market.